Holen Sie sich die Stockscreener-App
0.5792
6.66%
-0.0413
Handel nachbörslich:
.55
-0.0292
-5.04%
Schlusskurs vom Vortag:
$0.6205
Offen:
$0.6187
24-Stunden-Volumen:
385.47K
Relative Volume:
1.00
Marktkapitalisierung:
$19.44M
Einnahmen:
$3.04M
Nettoeinkommen (Verlust:
$-33.97M
KGV:
-0.4355
EPS:
-1.33
Netto-Cashflow:
$-52.47M
1W Leistung:
-10.63%
1M Leistung:
-47.82%
6M Leistung:
-71.33%
1J Leistung:
-88.42%
1-Tages-Spanne:
$0.5748
$0.6191
1-Wochen-Bereich:
$0.5748
$0.6563
52-Wochen-Spanne:
$0.4619
$5.7399
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Vergleichen Sie RANI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.5792 | 21.76M | 3.04M | -33.97M | -52.47M | -1.33 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics announces annual meeting results - Investing.com
Rani Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Consensus PT from Brokerages - Defense World
What is Zacks Small Cap’s Estimate for RANI Q3 Earnings? - Defense World
Q2 Earnings Estimate for RANI Issued By Zacks Small Cap - Defense World
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 7% – Here’s What Happened - Defense World
Rani Therapeutics Secures $4.3M via Series D Warrant - TipRanks
Rani Therapeutics strikes deal to issue new warrants - Investing.com
Rani Therapeutics strikes deal to issue new warrants By Investing.com - Investing.com UK
Rani Therapeutics Announces Research Agreement with Chugai - GlobeNewswire
Rani Therapeutics explores oral delivery of Chugai’s drugs - Investing.com Australia
RANI: 1Q:25 Financial Results - MSN
Rani Therapeutics (RANI) Partners with Chugai for Innovative Research | RANI Stock News - GuruFocus
Rani Therapeutics explores oral delivery of Chugai’s drugs By Investing.com - Investing.com India
Rani Therapeutics Enters Research Agreement with Chugai Pharmaceutical to Explore Oral Delivery Technology for Antibody Development - Nasdaq
Breakthrough: Rani's Oral Biologics Platform Matches Injectable Drugs in Chugai Partnership Study - Stock Titan
Oppenheimer Has Lowered Expectations for Rani Therapeutics (NASDAQ:RANI) Stock Price - Defense World
RANI Stock Update: Analyst Maintains Rating, Lowers Price Target | RANI Stock News - GuruFocus
Oppenheimer cuts Rani Therapeutics target to $4, keeps Outperform - Investing.com Australia
Oppenheimer cuts Rani Therapeutics target to $4, keeps Outperform By Investing.com - Investing.com Nigeria
Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating - marketscreener.com
Oppenheimer Adjusts Rani Therapeutics (RANI) Price Target | RANI Stock News - GuruFocus
Rani Therapeutics Highlights Promising Preclinical Data - TipRanks
Rani Therapeutics Q1 2025 Earnings: EPS Misses at -$0.22, Revenue Surpasses Estimates at $0.2 Million - GuruFocus
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewswire
Rani Therapeutics Q1 Net Income USD -12.738 Million - marketscreener.com
Rani Therapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Rani Therapeutics Achieves Major Milestone: Oral Obesity Drug Shows Equal Success to Injections in Latest Data - Stock Titan
Ratio Analysis: Unpacking Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Rani Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com India
Rani Therapeutics faces Nasdaq delisting over market value - Investing.com
Rani Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - ADVFN
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday - Defense World
Rani Therapeutics Board Restructures After DeBuono’s Retirement - TipRanks
Ratio Examination: Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Daily Progress: XPLR Infrastructure LP (XIFR) Drop -1.51, Closing at 8.46 - DWinneX
Market Recap: PowerFleet Inc (AIOT)’s Negative Momentum, Closing at 5.12 - DWinneX
Market Highlights: Clear Channel Outdoor Holdings Inc (CCO) Ends on a Low Note at 1.02 - DWinneX
Post-Trade Analysis: Baytex Energy Corp (BTE) Climbs 0.61, Closing at 1.65 - DWinneX
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33 - Defense World
SEC Form DEFA14A filed by Rani Therapeutics Holdings Inc. - Quantisnow
HC Wainwright Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - Defense World
What is Zacks Small Cap’s Forecast for RANI FY2025 Earnings? - Defense World
Rani Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.33 Consensus PT from Analysts - Defense World
Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains - TipRanks
BTIG maintains Buy on Rani Therapeutics stock, $14 target - Investing.com Australia
RANI: 2024 Financial Results - Yahoo Finance
Stifel maintains Buy on Rani Therapeutics, $8 target By Investing.com - Investing.com South Africa
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):